Plain-English translation of NCT06731621 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a small pilot study testing whether —a compound being studied for its potential to help people with depression—might work for autistic adults whose depression hasn't responded to standard antidepressants. You would receive two doses of the medication in supervised sessions, one week apart, along with therapy support from trained professionals. The researchers want to understand how this medication affects your brain and mood, and whether it might be safe and helpful for this group.
Many autistic adults with depression find that standard antidepressants don't work well enough for them. Researchers want to explore whether this medication, given in a carefully controlled setting with professional support, could be a new option for people in this situation.
You likely qualify if…
You likely don't qualify if…
You would start with a screening visit and a 2–4 week period to safely stop your current antidepressants, with weekly check-ins with a study psychiatrist. Then you would have a baseline visit with questionnaires and a brain scan (about 45 minutes). Two weeks later, you would attend two medication sessions one week apart, held at the hospital in a special treatment room—each session lasts 6–8 hours and includes trained therapists present the entire time. You would receive a lower practice dose first, then a treatment dose the following week, and be monitored closely for safety throughout.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Canada